Highlights and Quick Summary
- Total non-current liabilities for the quarter ending June 30, 2023 was $24.3 Million (a -3.17% decrease compared to previous quarter)
- Year-over-year quarterly Total non-current liabilities decreased by -8.61%
- Annual Total non-current liabilities for 2022 was $25.9 Million (a -9.99% decrease from previous year)
- Annual Total non-current liabilities for 2021 was $28.7 Million (a 68335.71% increase from previous year)
Visit stockrow.com/DYN
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Total non-current liabilities of Dyne Therapeutics, Inc.
Most recent Total non-current liabilitiesof DYN including historical data for past 10 years.Interactive Chart of Total non-current liabilities of Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc. Total non-current liabilities for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2023 | $24.32 | $25.12 | – | – | – |
| 2022 | $25.87 | $26.61 | $27.35 | $28.07 | $25.87 |
| 2021 | – | – | $28.74 | $29.41 | $28.74 |
| 2020 | – | – | – | $9.95 | – |
| 2019 | $0.04 | – | – | – | $0.04 |
Business Profile of Dyne Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology